Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the company outright for about $180m more.
Biopharmaceutical company Sosei Group agreed on Tuesday to pay £35m ($45m) for a 25.6% stake in UK-based RNA therapy developer Mina Therapeutics and an option to buy the company.
Mina is working on an RNA activation platform that will treat disease by activating key genes, and its lead product is a prospective liver cancer treatment called MTL-CEBPA which is currently in a phase1/2a outreach study.
The company’s technology is based on technology developed by its founder and licensed to it…